Good morning, everyone, and nice to see you again after we took an all-too-quick, day-long respite. Happily, we are greeted by clear, blue skies and a calming breeze wafting over the Pharmalot campus. So we are celebrating this good fortune with a few cups of stimulation. Our choice today is wild mountain blueberry. As always, you are invited to join us. The neurons need all the help they can get, yes? Meanwhile, we have assembled the latest laundry list of interesting items for you to peruse. We hope you have a pleasant and productive day and, of course, do keep in touch. Saucy tips, insights, and delightful secrets make the world go round. …
Companies that sell sexual health products and medicines over the internet are shifting their marketing strategies to highlight the availability of mail-order emergency contraception, commonly known as morning-after pills, The Wall Street Journal reports. Some are also using their emergency birth control advertising to protest government moves against reproductive rights, including the U.S. Supreme Court elimination of the constitutional right to an abortion when it overturned Roe v. Wade. The new, more-political campaigns advertising direct-to-consumer emergency contraception are rolling out as retailers ration the pills amid a surge in demand.
Sanofi says uninsured diabetes patients in the U.S. will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug, Reuters tells us. The new price is down from the prior out-of-pocket cost of $99 and will be effective from July 1. In March, the U.S. House passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35. Sanofi, Eli Lilly, and Novo Nordisk hold 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin at $35 per month.
Create a display name to comment
This name will appear with your comment